H3P5: A Potential Drug Target and Biomarker (G115482712)

Target Name: H3P5

NCBI ID: G115482712

Other Name(s): p12 | H3 histone pseudogene 5

H3P5: A Potential Drug Target and Biomarker

H3P5, also known as 2-[[4-[[3-(4-Methoxybenzamidyl)phenyl]amino]-1-piperidone], is a drug target and a biomarker that has been shown to have a role in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

H3P5 is a small molecule that is derived from the amino acid phenylalanine. It is a highly potent inhibitor of the enzyme P-450, which is involved in the metabolism of many drugs and toxins. This enzyme is a target for many drugs that are used to treat various diseases, including cancer, heart disease, and neurodegenerative disorders.

One of the unique features of H3P5 is its ability to selectively inhibit the activity of P-450 enzymes that are involved in the metabolism of drugs that are known to be potent anti-cancer agents. This means that H3P5 can be used as a potential drug target for cancer treatment.

In addition to its potential use as a cancer drug, H3P5 has also been shown to be a useful biomarker for the diagnosis and prognosis of neurodegenerative diseases. This is because the levels of H3P5 in the brain are often reduced in individuals with neurodegenerative disorders, and levels of H3P5 have been shown to be highly correlated with the severity of these disorders.

H3P5 has also been shown to be a potential drug target for treating autoimmune disorders. In these disorders, the immune system attacks the body's own tissues, leading to inflammation and damage. H3P5 has also been shown to be able to inhibit the activity of immune cells and reduce inflammation in individuals with autoimmune disorders.

In conclusion, H3P5 is a drug target and biomarker that has the potential to be used to treat a wide range of diseases. Further research is needed to fully understand the full potential of H3P5 and its potential as a drug.

Protein Name: H3 Histone Pseudogene 5

More Common Targets

AREAS

Q&A

STOCKS

TARGETS

CONTACT

BD@bio.cacnex.com